This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to assess the effects of CoQ on slowing the progressive impairment of Parkinson disease in early, otherwise untreated subjects. Parkinson disease (PD) is a progressive, neurodegenerative disease that affects over 1,000,000 Americans. It affects approximately one percent of persons over the age of 65. Coenzyme Q10 (CoQ) (2,3-dimethoxy-5-methylbenzoquinone), also known as ubiquinone, is a lipid-soluble benzoquinone derivative structurally similar to vitamin K. It is classified as a dietary supplement and is available commercially to the public over-the-counter (OTC). CoQ occurs naturally and is present in relatively high concentrations in the heart, liver, kidney and pancreas. Intracellular synthesis is the major source of CoQ, although some of it is acquired through the diet. Levels of CoQ from various tissues, including the brain, decline in humans with aging (Ernester and Dallner, 1995). The reasons for this decline and the contribution that the decline may have to diseases that occur more commonly in the elderly remain uncertain. Reduced levels of CoQ have been reported patients with heart failure, cardomyopathies, cancer, and some neurological diseases, including Parkinson disease (Ernster et al., 1995;Matsubara et al., 1991;Molina et al., 2002;Musumeci et al., 2001;Pepping 1999;Yamagami et al., 1981). An NIH-supported phase II trial (Shults et al., 2002) demonstrated that treatment of early Parkinson disease subjects with high dosages of CoQ was safe and well tolerated. There was a positive trend for treatment with CoQ to slow the progressive impairment. This phase III study is designed to confirm and extend the results of the phase II study.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Lavigne, Katie M; Woodward, Todd S (2018) Hallucination- and speech-specific hypercoupling in frontotemporal auditory and language networks in schizophrenia using combined task-based fMRI data: An fBIRN study. Hum Brain Mapp 39:1582-1595
Milot, Marie-Hélène; Marchal-Crespo, Laura; Beaulieu, Louis-David et al. (2018) Neural circuits activated by error amplification and haptic guidance training techniques during performance of a timing-based motor task by healthy individuals. Exp Brain Res 236:3085-3099
Hsu, Simon; Rifkin, Dena E; Criqui, Michael H et al. (2018) Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease. J Vasc Surg 67:1855-1863.e1
Inker, Lesley A; Grams, Morgan E; Levey, Andrew S et al. (2018) Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis :
Egnot, Natalie Suder; Barinas-Mitchell, Emma; Criqui, Michael H et al. (2018) An exploratory factor analysis of inflammatory and coagulation markers associated with femoral artery atherosclerosis in the San Diego Population Study. Thromb Res 164:9-14
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Chen, Teresa K; Appel, Lawrence J; Grams, Morgan E et al. (2017) APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765-1769
Juraschek, Stephen P; Appel, Lawrence J; Miller 3rd, Edgar R (2017) Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. Am J Hypertens 30:871-875
Chen, Teresa K; Tin, Adrienne; Peralta, Carmen A et al. (2017) APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol 12:1771-1777

Showing the most recent 10 out of 1825 publications